🎉 Free to use until Sep 16, 2026 — try it out for our launch!
STOCKIQAISTOCKIQAI
עברית
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.31▲ 1.06%
TA-125₪4,050.45▲ 0.45%
S&P 5007,709.96▼ 0.18%
Dow Jones53,885.1▼ 0.85%
Nasdaq26,348.35▼ 0.06%
Russell 20003,001.55▼ 0.58%
Fear Index (VIX)15.31▲ 1.06%
TA-125₪4,050.45▲ 0.45%

MPLT

MapLight Therapeutics, Inc.

Health Care · ·

$13.28

▲ $0.36 (+2.8%)

Market Cap

$563.55M

Day Range

$12.71 - $13.74

52-Week Range

$9.10 - $40.43

Beta

—

Next Earnings

—

MPLT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.

🏢 Similar Stocks in the Same Sector

AAPG

Ascentage Pharma Group International - American Depository

AARD

Aardvark Therapeutics, Inc.

ABCL

AbCellera Biologics Inc. - Common

-28.1% (1Y)

Some data (financial/growth/valuation) is currently unavailable — the daily API quota was likely exhausted. The score is computed from 6 of 7 available categories. Try again later for the full analysis.
Investor Score
39/ 100F
🔴 Weak

This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer

📈11FTechnical
💰46D+Fundamental
🚀46D+Growth
💎43DValuation
📰74BNews
🏦—Quality
⚠️48D+Risk

Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%

🔍 Cross-Check

Overall Score

🔴 Bearish

Technical Trend

🔴 Bearish

Insiders

🔴 Bearish

✅ Why is the score relatively high?

  • 🟢 Earnings per share (EPS) growth: 82.4%
  • 🟢 Current ratio: 20.01
  • 🟢 NAV per share: $52.80
  • 🟢 Current ratio: 20.01

⚠️ What's concerning?

  • 🔴 Estimated fair value: -$297.88 vs. price $13.28 (-2343.1%)
  • 🔴 ATR: 23.7% of price
  • 🔴 Return on equity (ROE): -35.2% (negative)
  • 🔴 Free cash flow growth: -74.2%
  • 🔴 Net income growth: -107.7%

🚦 Quality & Risk Checks

🔴 Daily volatility (ATR)🟢 Liquidity risk

📰 News Trend

Based on real financial news (Finnhub)
🟢 Positive

Everyone's writing about MapLight Therapeutics, Inc.. News trend score: 74. Reason: 9 of the last 20 articles are positive, versus 5 negative.

🟢 Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. — ChartMill🔴 MapLight CEO on what investors missed in the biotech’s schizophrenia data — BioPharma Dive🟡 Traders are paying attention to the gapping stocks in Wednesday's session. — ChartMill

News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer

📈 Technical Analysis

Based on the last 195 trading days, calculated from real price data. Click an indicator for details and a chart.

🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 0 neutral)

Conclusions

  • 🔴Price vs. SMA 50 — Price is below the 50-day average
  • 🔴MACD — MACD histogram is negative — falling momentum
  • 🔴RSI — RSI 29.5 — oversold
  • 🔴Stochastic — %K 13.7 — oversold
  • 🔴ADX (trend strength) — ADX 44.6 — strong trend
  • 🔴Relative strength vs. S&P 500 — -59.3% over the last 3 months relative to the index
  • 🔴Bollinger Bands — Price is in the lower third of the Bollinger Bands (23%B) — weakness (chance of a recovery)
  • 🔴ROC (rate of change) — ROC 12 days: -64.8%
  • 🔴Parabolic SAR — Price is below the SAR point — downtrend
  • 🔴CMF (money flow) — CMF 20 days: -0.09

Wyckoff Method Analysis

A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.

Markdown

The stock is in a clear downtrend with no defined trading range in the period examined.

Medium confidence

Evidence Behind This Read

  • 🔴Falling price trend — A -55.3% change over the last 50 days, with no defined trading range.

The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.

🎯 Trade Planning (M.A.E.E Framework)

Based on a mechanical trading method: market structure → value zone → ATR-based exit point. Not investment advice — a calculation tool only.

1️⃣ Market Structure

Not enough history to determine market structure (200-day average required).

2️⃣ Value Zone

🟡 Price far from value zone

The price is currently far from the 50-day average — the method recommends waiting for a "pullback" before entering, rather than chasing prices.

Not enough data (ATR / support / resistance) to calculate a suggested exit point.

💰 Financial Health

Profitability

Gross Margin

—

Operating Margin

—

Net Margin

—

EBITDA Margin

—

Efficiency

ROE

-35.2%

ROA

-33.6%

ROIC

—

EPS

-$18.56

Balance Sheet

Cash

$46.73M

Total Debt

—

Current Ratio

20.01

Debt/Equity

—

Conclusions

  • 🔴Return on equity (ROE) — Return on equity (ROE): -35.2% (negative)
  • 🔴Return on assets (ROA) — Return on assets (ROA): -33.6% — weak
  • 🟢Current ratio (liquidity) — Current ratio: 20.01

🚀 Growth

Revenue

אין נתונים היסטוריים זמינים.

Earnings per Share (EPS)

Net Income

Free Cash Flow (FCF)

Conclusions

  • 🟢Earnings per share (EPS) growth — Earnings per share (EPS) growth: 82.4%
  • 🔴Free cash flow growth — Free cash flow growth: -74.2%
  • 🔴Net income growth — Net income growth: -107.7%

💎 Fair Value (Valuation)

Current Price

$13.28

Estimated Fair Value (DCF)

-$297.88

Gap

-2343.1%

🔴 Appears expensive relative to estimated value

Show all model (DCF) assumptions →

Year 1 Growth Rate

10.0%

Discount Rate (WACC)

9.0%

Terminal Growth Rate

2.5%

Projection Years

5

YearGrowth RateProjected FCFPresent Value
110.0%$-152.47M$-139.88M
28.1%$-164.86M$-138.76M
36.3%$-175.16M$-135.26M
44.4%$-182.83M$-129.52M
52.5%$-187.40M$-121.80M

Base FCF (last actual year)

$-138.61M

Terminal Value

$-2.96B

Present Value of Terminal Value

$-1.92B

Enterprise Value

$-2.59B

Net Debt

$0

Equity Value

$-2.59B

*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.

Book Value per Share

$52.80

Tangible Book Value per Share (Tangible NAV)

$52.80

Conclusions

  • 🔴DCF Fair Value — Estimated fair value: -$297.88 vs. price $13.28 (-2343.1%)
  • 🟢Tangible Net Asset Value (NAV) — NAV per share: $52.80
  • 🟡P/E — P/E: -0.7

🕴️ Insider Trading

Real transactions by officers and insiders, as reported to the SEC on Form 4 — 1 purchases and 24 sales out of the last 25 filings.

NameTransaction TypeDateSharesChangePrice
Lillie James WoodruffOpen Market Sale3.8.2026202,380-22,082$12.54
Cox TroyOpen Market Purchase28.7.202615,620+15,620$9.52
GILLIS JONATHANOpen Market Sale17.7.2026162,109-600$36.51
GILLIS JONATHANOpen Market Sale17.7.2026145,140-16,969$37.61
GILLIS JONATHANOpen Market Sale17.7.2026144,240-900$38.17
Kreitzer AnatolOpen Market Sale17.7.2026189,246-2,833$37.05
Kreitzer AnatolOpen Market Sale17.7.2026175,106-14,140$37.70
Kreitzer AnatolOpen Market Sale17.7.2026174,906-200$38.39
Kroeger Christopher A.Open Market Sale17.7.20261,246,455-16,779$37.90
Lillie James WoodruffOpen Market Sale17.7.2026224,462-2,077$37.90
Hanson KristopherOpen Market Sale17.7.2026145,823-1,130$37.90
Foff Erin PennockOpen Market Sale17.7.2026298,901-3,656$37.90
GILLIS JONATHANOpen Market Sale16.7.2026164,185-6,979$36.66
GILLIS JONATHANOpen Market Sale16.7.2026162,709-1,476$37.44
Kreitzer AnatolOpen Market Sale16.7.2026193,671-7,464$36.66
Kreitzer AnatolOpen Market Sale16.7.2026192,079-1,592$37.44
Kroeger Christopher A.Open Market Sale16.7.20261,291,417-40,899$36.46
Kroeger Christopher A.Open Market Sale16.7.20261,263,326-28,091$37.26
Kroeger Christopher A.Open Market Sale16.7.20261,263,234-92$37.96
Lillie James WoodruffOpen Market Sale16.7.2026230,077-5,009$36.45
Lillie James WoodruffOpen Market Sale16.7.2026226,551-3,526$37.26
Lillie James WoodruffOpen Market Sale16.7.2026226,539-12$37.96
Hanson KristopherOpen Market Sale16.7.2026150,295-4,776$36.45
Hanson KristopherOpen Market Sale16.7.2026146,964-3,331$37.26
Hanson KristopherOpen Market Sale16.7.2026146,953-11$37.96

📉 Short Interest

Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.

Monthly Trend — Open Short Interest

↑+39.1%

3,586,196 shares short as of 2026-07-15 · vs. 2,577,722 on 2026-06-30

Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.

Weekly Trend — Daily Short-Sale Activity

↓-9.4%

52.6% of trading volume this week was short selling, vs. 58.1% the prior week

Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.

📰 News & Sentiment

Sentiment based on basic keywords (not AI) — 9 positive, 6 neutral, 5 negative out of the last 20 articles.